Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 6/20 | 0.41 |
| ▸ | NOS3 | P29474 | 5/20 | 0.41 |
| ▸ | NOS1 | P29475 | 5/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162838 | 0.83 | KDM4E (0.41) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL13046396 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL15247864 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1CA12CA2CA3 | |
| SCHEMBL20080155 | 0.81 | CYP2D6 (0.35) | KDM4EALDH1A1CYP2D6HRH1KCNH2 | |
| SCHEMBL13209122 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL24352097 | 0.79 | NCF1 (0.43) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL17285923 | 0.79 | SMN1; SMN2 (0.43) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL15473810 | 0.79 | CA12 (0.38) | KDM4EALDH1A1CA12CA2CA3 | |
| SCHEMBL16222435 | 0.78 | GNAI3 (0.44) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL16996947 | 0.78 | TSHR (0.48) | KDM4EALDH1A1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312180-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | East China University Of Science And Technology (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| WO-2016192609-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | 华东理工大学 | 2016-12-08 | — | — | WO | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | KDM4E 3565/4885ALDH1A1 3163/4885NOS2 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.